Drug Reimbursement Recommendation - lanadelumab (Takhzyro) + certolizumab pegol (Cimzia)

Today, CADTH has issued final recommendations for:

lanadelumab (Takhzyro)

Indications: Hereditary angioedema, prevention
Recommendation: Reimburse with clinical criteria and/or conditions

For more information

certolizumab pegol (Cimzia)

Indications: Psoriasis, moderate to severe plaque
Recommendation: Reimburse with clinical criteria and/or conditions

For more information